VKTX Completes Enrollment in First Late-Stage Study on Obesity DrugZacks Investment Research • 11/20/25
Viking Therapeutics, Up 62% Since August, Lingers In Buy Zone On An Obesity WinInvestors Business Daily • 11/19/25
Viking Therapeutics, Inc. (VKTX) Presents at Jefferies London Healthcare Conference 2025 TranscriptSeeking Alpha • 11/19/25
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735PRNewsWire • 11/19/25
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025PRNewsWire • 11/06/25
Billionaire Stanley Druckenmiller Dropped Nvidia and Palantir Stock and Is Piling into 2 Stocks Set to Win in One of the Decade's Hottest Growth Markets.The Motley Fool • 11/05/25
Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025PRNewsWire • 10/29/25
Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales NilZacks Investment Research • 10/23/25
Viking Therapeutics Q3 Earnings: What We Learned (And Why We Should Keep Faith)Seeking Alpha • 10/23/25
Viking Bolts Higher On 'Lightning' Speed Enrollment In Obesity StudiesInvestors Business Daily • 10/23/25